Cargando…
Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity
Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs is responsible for tumor initiation, progression, recurrence and chemo-resistance. Celecoxib is one of the most commonly used non-steroidal anti-inflam...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777769/ https://www.ncbi.nlm.nih.gov/pubmed/29383157 http://dx.doi.org/10.18632/oncotarget.23250 |
_version_ | 1783294243965501440 |
---|---|
author | Huang, Chaolin Chen, Yuanhong Liu, Hang Yang, Jing Song, Xuejing Zhao, Junping He, Na Zhou, Chengji J. Wang, Yongping Huang, Changjiang Dong, Qiaoxiang |
author_facet | Huang, Chaolin Chen, Yuanhong Liu, Hang Yang, Jing Song, Xuejing Zhao, Junping He, Na Zhou, Chengji J. Wang, Yongping Huang, Changjiang Dong, Qiaoxiang |
author_sort | Huang, Chaolin |
collection | PubMed |
description | Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs is responsible for tumor initiation, progression, recurrence and chemo-resistance. Celecoxib is one of the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs), which have chemo-preventive activity against cancers, including breast cancer and colorectal cancer. However, the mechanisms by which NSAIDs exert its cancer prevention effects have yet been completely understood. In the present study, we investigated for the first time the effect of celecoxib on breast CSCs inhibition and its potential molecular mechanisms. Our results demonstrated that celecoxib suppresses CSC self-renewal, sensitizes chemo-resistance, inhibits epithelial to mesenchymal transition (EMT), and attenuates metastasis and tumorigenesis. Further exploring the underlying mechanism revealed that celecoxib targets breast CSCs by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity. Our findings suggest that celecoxib, by targeting CSCs, may be used as an adjuvant chemotherapy drug to improve breast cancer treatment outcomes. |
format | Online Article Text |
id | pubmed-5777769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57777692018-01-30 Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity Huang, Chaolin Chen, Yuanhong Liu, Hang Yang, Jing Song, Xuejing Zhao, Junping He, Na Zhou, Chengji J. Wang, Yongping Huang, Changjiang Dong, Qiaoxiang Oncotarget Research Paper Pharmacological targeting of breast cancer stem cells (CSCs) is highly promising for the treatment of breast cancer, as the small population of CSCs is responsible for tumor initiation, progression, recurrence and chemo-resistance. Celecoxib is one of the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs), which have chemo-preventive activity against cancers, including breast cancer and colorectal cancer. However, the mechanisms by which NSAIDs exert its cancer prevention effects have yet been completely understood. In the present study, we investigated for the first time the effect of celecoxib on breast CSCs inhibition and its potential molecular mechanisms. Our results demonstrated that celecoxib suppresses CSC self-renewal, sensitizes chemo-resistance, inhibits epithelial to mesenchymal transition (EMT), and attenuates metastasis and tumorigenesis. Further exploring the underlying mechanism revealed that celecoxib targets breast CSCs by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity. Our findings suggest that celecoxib, by targeting CSCs, may be used as an adjuvant chemotherapy drug to improve breast cancer treatment outcomes. Impact Journals LLC 2017-12-14 /pmc/articles/PMC5777769/ /pubmed/29383157 http://dx.doi.org/10.18632/oncotarget.23250 Text en Copyright: © 2017 Huang et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Huang, Chaolin Chen, Yuanhong Liu, Hang Yang, Jing Song, Xuejing Zhao, Junping He, Na Zhou, Chengji J. Wang, Yongping Huang, Changjiang Dong, Qiaoxiang Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity |
title | Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity |
title_full | Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity |
title_fullStr | Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity |
title_full_unstemmed | Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity |
title_short | Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E(2) and down-regulating the Wnt pathway activity |
title_sort | celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin e(2) and down-regulating the wnt pathway activity |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777769/ https://www.ncbi.nlm.nih.gov/pubmed/29383157 http://dx.doi.org/10.18632/oncotarget.23250 |
work_keys_str_mv | AT huangchaolin celecoxibtargetsbreastcancerstemcellsbyinhibitingthesynthesisofprostaglandine2anddownregulatingthewntpathwayactivity AT chenyuanhong celecoxibtargetsbreastcancerstemcellsbyinhibitingthesynthesisofprostaglandine2anddownregulatingthewntpathwayactivity AT liuhang celecoxibtargetsbreastcancerstemcellsbyinhibitingthesynthesisofprostaglandine2anddownregulatingthewntpathwayactivity AT yangjing celecoxibtargetsbreastcancerstemcellsbyinhibitingthesynthesisofprostaglandine2anddownregulatingthewntpathwayactivity AT songxuejing celecoxibtargetsbreastcancerstemcellsbyinhibitingthesynthesisofprostaglandine2anddownregulatingthewntpathwayactivity AT zhaojunping celecoxibtargetsbreastcancerstemcellsbyinhibitingthesynthesisofprostaglandine2anddownregulatingthewntpathwayactivity AT hena celecoxibtargetsbreastcancerstemcellsbyinhibitingthesynthesisofprostaglandine2anddownregulatingthewntpathwayactivity AT zhouchengjij celecoxibtargetsbreastcancerstemcellsbyinhibitingthesynthesisofprostaglandine2anddownregulatingthewntpathwayactivity AT wangyongping celecoxibtargetsbreastcancerstemcellsbyinhibitingthesynthesisofprostaglandine2anddownregulatingthewntpathwayactivity AT huangchangjiang celecoxibtargetsbreastcancerstemcellsbyinhibitingthesynthesisofprostaglandine2anddownregulatingthewntpathwayactivity AT dongqiaoxiang celecoxibtargetsbreastcancerstemcellsbyinhibitingthesynthesisofprostaglandine2anddownregulatingthewntpathwayactivity |